Brought to you by 
AZ gets US and Canadian rights to Actavis' branded respiratory portfolio
01 Jun 2021
Executive Summary
AstraZeneca PLC will pay $600mm up front, plus low-single-digit royalties, to acquire rights to Actavis PLC’s branded respiratory drug portfolio in the US and Canada. AZ will also hand over $100mm related to undisclosed contractual consents and approvals pertaining to previous collaborations with Actavis.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ gets US and Canadian rights to Actavis' branded respiratory portfolio
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice